Notice of Results
10 oct. 2019 09h30 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019 Oxford, UK, and...
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
07 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes...
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
03 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile...
Block Listing Six Month Review
03 oct. 2019 02h00 HE
|
Summit Therapeutics plc
BLOCK LISTING SIX MONTHLY RETURN (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 3 October 2019 Name of applicant:Summit Therapeutics plcName of scheme:2005 EMI...
Summit Therapeutics to Host R&D Day 7 October 2019
25 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc...
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
24 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US,...
Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
18 sept. 2019 02h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship...
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
05 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference New Mechanism Antibiotic...
Summit Therapeutics to Participate in Upcoming Investor Conferences
04 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Participate in Upcoming Investor Conferences Oxford, UK, and Cambridge, MA, US, 4 September 2019 – Summit...
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
01 août 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 1 August 2019 – Summit...